Traditional blood sampling is invasive, requires trained healthcare professionals, and often involves complex logistics such as biohazard handling and cold-chain transportation. These limitations make routine testing and large-scale health monitoring highly impractical, particularly in remote, underserved, or resource-limited regions.
Based on many years of research at KTH within microsystems technology, Samplimy is developing a new generation of microsampling devices designed to make the collection of biological samples easier, more accessible and scalable. Its technology enables users to comfortably and easily collect a small, precise sample volume to be sent back to a lab using regular post. Samplimy's product portfolio includes the CWB-1 for capillary whole blood sampling and the ISF-1 for sampling dermal interstitial fluid. The latter provides access to biomarkers in the tissue environment and unlocks new insights in areas such as drug development and skin health.
By simplifying sample collection, Samplimy aims to enable more frequent and longitudinal sampling, improving access to biological data in research and healthcare. Potential applications include clinical research, decentralized clinical trials, biomarker discovery, population screening and precision medicine. The company is currently focused on providing research customers with a robust, user-friendly and cost-effective microsampling platform.
The omics revolution has made it possible to read thousands of biomarkers from a single microliter of sample, and AI is now turning multimodal layers of biodata into new insights. The bottleneck is no longer what we can read from a sample, but how easily we can get one. Making collection painless and self-performed changes what is measurable, from a snapshot taken a handful of times in a lifetime to a longitudinal record of our biology. We are starting with research customers where the need is immediate, but we are building products for healthcare systems that will demand more accessible and high-frequency biomarkers. With the support from KTH Ventures, we can accelerate the development and commercialization of our microsampling technology. says Patrik Nilsson, CEO of Samplimy.
I have supported and followed the technology development over several years and are very excited to support the spin-off Samplimy bringing this KTH research to the market. The ability to collect biological samples painlessly and in a more practical manner could significantly expand the possibilities for longitudinal studies, decentralized clinical trials and large-scale biomarker monitoring. Samplimy is a strong example of how deeptech developed at KTH can address important challenges in healthcare,” says Daniel Carlsson, Investment Director at KTH Ventures.
Samplimy's team includes CEO Patrik Nilsson, CTO and co-founder Federico Ribet, CCO Bernd Kuntscher and CSO Professor Niclas Roxhed.
About KTH Ventures AB
KTH Ventures creates and invests in early-stage start-up companies based on research or education at KTH. The aim is to make research, new ideas and knowledge from KTH generate a positive impact in society. The investment portfolio comprises more than 60 companies in many technology fields and development stages. See: www.kthventures.se
About Samplimy Medical AB
Samplimy is a Stockholm-based medtech company developing pioneering microsampling technology to unlock access to biological information at greater frequency and scale. Its devices enable painless, self-performed collection of capillary blood and dermal interstitial fluid for research and healthcare applications.
For more information: Samplimy
For inquiries, please contact: contact@samplimy.com
